NCT00095043
Completed
Phase 3
A 12-Month, Randomized, Double-Blind, Placebo-Controlled, Parallel Groups, Multicenter Long-Term Safety Study of MK0928 in the Treatment of Elderly Outpatients With Primary Insomnia
ConditionsInsomnia
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Insomnia
- Sponsor
- H. Lundbeck A/S
- Enrollment
- 320
- Primary Endpoint
- Safety and tolerability after 12 months of treatment
- Status
- Completed
- Last Updated
- 9 years ago
Overview
Brief Summary
The purpose of this trial is to study the safety of MK0928 on insomnia in the elderly.
Detailed Description
The duration of treatment is 1 year.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diagnosis of Insomnia
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Safety and tolerability after 12 months of treatment
Secondary Outcomes
- Discontinuation symptoms and rebound insomnia using sleep diary and Tyrer Withdrawal Symptom Questionnaire
Similar Trials
Completed
Phase 3
Efficacy and Safety of MK0928 for Insomnia in Adults (0928-003)(COMPLETED)InsomniaNCT00095069H. Lundbeck A/S600
Completed
Phase 3
An Investigational Study of MK0928 in Adult Outpatients With Insomnia (0928-014)(COMPLETED)InsomniaNCT00103818H. Lundbeck A/S900
Completed
Phase 3
Study of MK0928 in Healthy Adult Volunteers in a Model of Insomnia (0928-006)(COMPLETED)InsomniaNCT00102167H. Lundbeck A/S663
Terminated
Phase 3
Elderly Primary Insomnia Polysomnographic Study (0928-002)(TERMINATED)Primary InsomniaNCT00094666H. Lundbeck A/S465
Withdrawn
Phase 3
An Investigational Drug Study in Healthy Adult Volunteers in a Model of Insomnia (0928-007)InsomniaNCT00102154H. Lundbeck A/S